High-speed liquid chromatographic method for the monitoring of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, in human plasma
| Autor: | Patrice Combe, Daniel F. Chollet, Eliane Castella, Valdo Arnera |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Chromatography
Metabolite Reproducibility of Results General Chemistry Carbamazepine High-performance liquid chromatography Circadian Rhythm chemistry.chemical_compound chemistry Specific surface area Calibration medicine Humans Protein precipitation Anticonvulsants Spectrophotometry Ultraviolet Acetonitrile Quantitative analysis (chemistry) Chromatography High Pressure Liquid Active metabolite medicine.drug |
| Zdroj: | Journal of Chromatography B: Biomedical Sciences and Applications. 683:237-243 |
| ISSN: | 0378-4347 |
| DOI: | 10.1016/0378-4347(96)00116-8 |
| Popis: | The assays of antiepileptic drugs, which are performed by central laboratories in Phase II and III clinical trials, require both a very fast turn-around time and a suitable specificity. In order to decrease the run time and to keep the powerful specificity of the liquid chromatography (HPLC), the use of a reversed-phase 1.5 microns monosized non-porous silicon dioxide microspheres column instead of regular columns containing spherical porous C18 material was studied. The determination of carbamazepine (CBZ) and its active metabolite, carbamazepine-10,11-epoxide (CBZ-E), in human plasma or serum was chosen to demonstrate the utility of these columns. As a prerequisite of this work, no modification of a regular HPLC system was allowed. The samples were prepared in autosampler vials by protein precipitation with acetonitrile, followed by a quick centrifugation. Without any change to a conventional HPLC system, CBZ and CBZ-E are well separated in less than 2.5 min using a Kovasil MS C14 column. No interference was observed with endogenous compounds and with nine antiepileptic drugs commonly prescribed as co-medication, and their metabolites. Due to the very low specific surface area of the packing, the required organic modifier volume per chromatographic run was decreased by a factor of 25. The method was validated. The developed method is well suited for the determination of CBZ and CBZ-E in clinical trials. It can be easily adapted to the monitoring of other antiepileptic drugs. No modification of a regular HPLC system was required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|